Brief: AB Science-Update On EMA Timetable For Masitinib Marketing Authorization
18/09/2023 17:10
Sept 18 (Reuters) - AB Science SA ABS.PA :
* AB SCIENCE PROVIDES AN UPDATE ON THE EMA TIMETABLE FOR
EXAMINATION OF THE MASITINIB MARKETING AUTHORIZATION APPLICATION
IN ALS
* BASED ON UPDATED TIMETABLE, A DECISION FROM EUROPEAN
MEDICINES
AGENCY IS EXPECTED DURING Q1 OF 2024
Source text for Eikon: ID:nGNX35mzTs
Further company coverage: ABS.PA
(Gdansk Newsroom)
((gdansk.newsroom@thomsonreuters.com; +48 58 769 66 00;))
Recent news on AB Science SA
See all newsBrief: AB Science Temporarily Halts Europe Clinical Trials Ahead Of Strategic Reorganization
Brief: AB Science Says FDA Granted Status Of Minor Use In Major Species For Masivet
Brief: AB Science Says Co Received Japanese Patent Protection To Use Masitinib In Progressive MS Until 2041
Brief: AB Science Phase 1 AML Study Of AB8939 Shows 100% Partial Response Rate
Brief: AB Science Receives Notice Of Allowance For European Patent Covering Masitinib Until 2040 In Treatment Of Sickle Cell Disease